Best GLP-1 telehealth services of 2026, judged on everything except the price tag

Price ladders live on our cheapest-providers page. This page ranks the service around the vial: clinician model, support access, pharmacy transparency, refill logistics, and how hard it is to leave — the factors that decide whether a program works in month four, not just month one.

Material connection: NexLife is a commercial partner of this site and appears on this page; partner links may earn us a commission at no extra cost to you. Partner status never changes a ranking — every ranking here is computed from the public dataset, and NexLife’s own figures remain labeled operator until independently verified. Full disclosure.

Clinician model: who actually evaluates you

The legal floor in 2026 is a real, patient-specific clinical evaluation — the FDA's February warning-letter sweep targeted exactly the questionnaire-mill model. Ro and Hims run mature synchronous and asynchronous visit systems with identifiable medical groups (Ro ↗ · Hims ↗). Eden and Mochi document clinician review in their flows (Eden ↗ · Mochi ↗). NexLife advertises personalized one-on-one physician care and 24/7 medical support inside its flat price — an operator claim we treat like its prices: listed, labeled, and queued for verification (NexLife ↗). Any provider whose "evaluation" is a two-minute form with no clinician name attached fails our methodology outright.

Pharmacy transparency

The single best service-quality signal in compounded GLP-1s is whether a provider names its 503A pharmacy unprompted. Eden's in-house pharmacy ownership is a reported strength; Henry discloses its fulfillment structure; the identity and licensure of NexLife's dispensing pharmacy is our top open item for that provider. A company that treats its pharmacy's name as a secret is asking you to inject a product with no paper trail — that's disqualifying here regardless of price.

Support, refills, and the exit door

Titration means dose changes every four weeks early on, so support latency is a real cost: a program that takes ten days to answer a dose question effectively skips your titration step. NexLife's CARE360 and 24/7 support claims and Henry's flat-bundle support are the strongest listed offers at the budget end; Ro and Hims have the deepest reported support infrastructure overall. On exits: NexLife claims cancel-anytime with 30 days' notice and a "come back anytime" policy; month-to-month structures at Henry and Mochi are reported as low-friction. We verify cancellation by reading the terms and, where possible, walking the flow — a program you can't leave isn't affordable at any price.

The honest scoreboard

Best overall service infrastructure on reported evidence: Ro. Best budget-tier service claims: NexLife, pending verification of its support and pharmacy items. Best pharmacy transparency: Eden. Most improved-worth-watching: the breakout names — Orderly, Remedy, Trimi — whose service models we haven't verified at all, which is precisely why they sit on the watchlist rather than in these rankings.

2026 legal reality: the FDA declared the tirzepatide shortage resolved in December 2024 and bulk 503B compounding ended in March 2025. What remains legal is patient-specific 503A compounding with a documented clinical need — and the FDA sent roughly thirty warning letters to GLP-1 telehealth marketers in February 2026. Compliance posture is now a ranking factor here, not a footnote. Details in our methodology.